Literature DB >> 12217725

Respiratory syncytial virus infections in children and adults.

C L Collins1, A J Pollard.   

Abstract

Respiratory syncytial virus is the leading cause of hospital admission for lower respiratory tract infection in young children and appears to be responsible for a significant burden of disease in adults, particularly the elderly and the immunocompromised. In this review, we describe the epidemiology, diagnosis and clinical manifestations of infection attributed to this virus. We also consider current therapeutic and prophylactic options and appraise strategies for vaccination that are in clinical trials. Copyright 2002 The British Infection Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217725     DOI: 10.1053/jinf.2001.1016

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  12 in total

1.  Role of metapneumovirus in viral respiratory infections in young children.

Authors:  José Ordás; José Antonio Boga; Marta Alvarez-Argüelles; Laura Villa; Cristina Rodríguez-Dehli; María de Oña; Julián Rodríguez; Santiago Melón
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).

Authors:  Ian Mitchell; S K Wong; B Paes; M Ruff; C Bjornson; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-04       Impact factor: 3.267

3.  Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?

Authors:  Candice Bjornson; Parco Chan; Abby Li; Bosco Paes; Krista L Lanctôt; Ian Mitchell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-19       Impact factor: 3.267

4.  Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Carlos A Camargo; Adit A Ginde; Sunday Clark; Charles P Cartwright; Ann R Falsey; Dennis E Niewoehner
Journal:  Intern Emerg Med       Date:  2008-09-30       Impact factor: 3.397

5.  Genetic variability of group A human respiratory syncytial virus strains circulating in Germany from 1998 to 2007.

Authors:  Janine Reiche; Brunhilde Schweiger
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

Review 6.  Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets.

Authors:  Mary K McCarthy; Jason B Weinberg
Journal:  Mediators Inflamm       Date:  2012-05-15       Impact factor: 4.711

7.  The eukaryotic elongation factor 1A is critical for genome replication of the paramyxovirus respiratory syncytial virus.

Authors:  Ting Wei; Dongsheng Li; Daneth Marcial; Moshin Khan; Min-Hsuan Lin; Natale Snape; Reena Ghildyal; David Harrich; Kirsten Spann
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

Review 8.  Functional Impairment of Mononuclear Phagocyte System by the Human Respiratory Syncytial Virus.

Authors:  Karen Bohmwald; Janyra A Espinoza; Raúl A Pulgar; Evelyn L Jara; Alexis M Kalergis
Journal:  Front Immunol       Date:  2017-11-27       Impact factor: 7.561

9.  Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention.

Authors:  Jinghan Jenny Chen; Parco Chan; Bosco Paes; Ian Mitchell; Abby Li; Krista L Lanctôt
Journal:  PLoS One       Date:  2015-08-03       Impact factor: 3.240

10.  Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study.

Authors:  Jesse Papenburg; Mahwesh Saleem; Johannes Teselink; Abby Li; Georges Caouette; Édith Massé; Krista L Lanctôt
Journal:  Pediatr Infect Dis J       Date:  2020-08       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.